Literature DB >> 26604225

Extremely high HIV-1 viral load in a patient with undiagnosed clinical indicator disease for HIV infection.

Stuart Flanagan1, Sophia De Saram2, Rageshri Dhairyawan3.   

Abstract

We report a case of a new diagnosis of HIV with an extremely high viral load presenting with HIV encephalopathy, in a 54-year-old woman who had been treated with 2 years of extended high-dose immunosuppressant therapy for a recalcitrant pruritic rash before diagnosis. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26604225      PMCID： PMC4680573          DOI： 10.1136/bcr-2015-210213

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.

Authors:  Harriet Mayanja-Kizza; Edward Jones-Lopez; Alphonse Okwera; Robert S Wallis; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen
Journal:  J Infect Dis       Date:  2005-02-08       Impact factor: 5.226

Review 2.  HIV testing and management of newly diagnosed HIV.

Authors:  Michael Rayment; David Asboe; Ann K Sullivan
Journal:  BMJ       Date:  2014-07-08

3.  Inhibition of HIV-1-specific T-cells and increase of viral load during immunosuppressive treatment in an HIV-1 infected patient with Chlamydia trachomatis induced arthritis.

Authors:  T Harrer; M Bäuerle; S Bergmann; K Eismann; E G Harrer
Journal:  J Clin Virol       Date:  2005-09-02       Impact factor: 3.168

4.  Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1.

Authors:  H Soudeyns; R Geleziunas; G Shyamala; J Hiscott; M A Wainberg
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

5.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Dynamics of co-infection with M. Tuberculosis and HIV-1.

Authors:  D Kirschner
Journal:  Theor Popul Biol       Date:  1999-02       Impact factor: 1.570

7.  Factors associated with pruritic papular eruption of human immunodeficiency virus infection in the antiretroviral therapy era.

Authors:  S L Chua; E H Amerson; K S Leslie; T H McCalmont; P E Leboit; J N Martin; D Bangsberg; T A Maurer
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

8.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Authors:  Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177
  8 in total
  1 in total

Review 1.  When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?

Authors:  Yi Zhang; Till Bärnighausen; Nir Eyal
Journal:  J Acquir Immune Defic Syndr       Date:  2019-06-01       Impact factor: 3.731
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.